The Personal Connected Health Alliance (PCHAlliance) and Consumer Technology Association (CTA) Health and Fitness Technology Division has announced a new, strategic collaboration around digital therapeutics research. The strategic collaboration aims to understand the current demand, adoption and market trends related to digital therapeutics among patients and health care professionals alongside technology and pharmaceutical companies.
Understanding Digital Therapeutics
The field of digital therapeutics, a subset of personal connected health, is gaining widespread attention as an alternative or enhancement of drug or in-person treatment. As part of the collaboration, the combined efforts of PCHAlliance and CTA will produce recommendations supporting a multi-year, multi-stakeholder collaboration to increase awareness, evidence and adoption of proven digital therapeutics approaches.
“We are very pleased to collaborate with CTA, and engage our respective communities to help define and shape this emerging approach for treating disease through digital technologies — as a substitute for traditional drug therapies or as a complement to enhance the effectiveness of drug therapies,” said Patricia Mechael, PhD, MHS, Executive Vice President, PCHAlliance in a statement. “For example, It is exciting to see recent developments in the use of virtual reality as an alternative to pain medication, demonstrating its potential to address the opioid epidemic in the U.S. This is just the tip of the iceberg. “We will work together and engage the full ecosystem to advance the understanding and widespread adoption of digital therapeutics while ensuring a supportive and enabling regulatory environment.”
